DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies

Jd Fuchs, Cecilia Morgan, Pierre‐Alexandre Bart, Nidhi Kochar, Nicole Frahm, Edith Swann, Peter B. Gilbert, Stephen C. DeRosa, B Graham, Gj Nabel, Hua‐Xin Liao, Barton F. Haynes, Georgia D. TomarasRetrovirology 2012 · DOI

Introduction

The extreme genetic diversity of HIV-1 remains a primary obstacle to developing an effective global vaccine. The virus is categorized into distinct clades (strains), and a vaccine designed for one clade often fails to provide protection against others. However, insights from the RV144 "Thai Trial"—the only HIV vaccine study to demonstrate even modest efficacy—revealed a critical immune signature: antibodies targeting the V1V2 loop of the HIV Envelope (Env) protein were correlated with a reduced risk of infection.

This study, part of the HIV Vaccine Trials Network (HVTN 077), evaluates whether prime-boost strategies using DNA vaccines and recombinant adenovirus vectors (rAd5 and rAd35) can elicit these critical V1V2-specific and cross-clade binding antibodies. By testing different combinations of these vectors, researchers aimed to identify the most effective regimen for inducing broad, potentially protective immunity.

Methodology

The HVTN 077 trial was a double-blinded, placebo-controlled study involving 192 healthy, HIV-uninfected participants. The research investigated four distinct vaccine regimens (T1–T4) utilizing Clade A Env inserts to determine their ability to generate cross-reactive antibodies:

  • T1: rAd35 prime followed by an rAd5 boost (conducted in Ad5-seronegative participants).
  • T2: DNA prime followed by an rAd5 boost (conducted in Ad5-seronegative participants).
  • T3: DNA prime followed by an rAd35 boost (conducted in Ad5-seronegative participants).
  • T4: DNA prime followed by an rAd35 boost (conducted in Ad5-seropositive participants).

The inclusion of T4 was specifically designed to assess whether pre-existing immunity to the common Ad5 virus would interfere with the vaccine's effectiveness when using the rarer rAd35 vector. Immune responses were measured four weeks after the final boost using a multiplex assay to quantify IgG binding antibody (bAb) responses. The evaluation targeted several standardized HIV-1 antigens, including Group M Consensus (Con S), Clades A, B, and C gp140 proteins, and novel gp70 V1V2 scaffolds (V1V2 VRC A and V1V2 Case A2).

Results

The study demonstrated that these prime-boost regimens successfully induced broad and specific antibody responses across all test groups.

High Response Frequency and Cross-Clade Breadth

Nearly all participants developed antibodies against Clade A (95.8%–100%) and the Group M Consensus (100%). Remarkably, despite using only Clade A inserts, the vaccines triggered high response rates for other strains: Clade B (92.1%–96.3%) and Clade C (76%–92%). This "cross-clade" success suggests that the regimens can induce immunity against conserved regions of the virus, which is essential for a vaccine intended for global use.

V1V2 Specificity

A significant majority of participants developed V1V2-specific antibodies for Clade A (83.8%–100%) and Clade B (51.9%–65.9%). This finding is a major milestone, as it confirms that these specific vector combinations can replicate the immune signature associated with protection in the RV144 trial.

Magnitude and Vector Immunity

While the frequency of response was consistent across groups, the magnitude of the Clade A V1V2 response (measured by Mean Fluorescent Intensity) was significantly higher in the DNA/rAd5 group (T2) compared to the rAd35/rAd5 group (T1) ($p=0.005$).

Furthermore, the study addressed the challenge of pre-existing adenovirus immunity. Many people have been naturally exposed to Ad5, which can neutralize Ad5-based vaccines before they can work. By using the rarer rAd35 vector in regimens T3 and T4, the researchers showed they could elicit strong immune responses even in individuals who were already seropositive for Ad5.

Conclusion

The HVTN 077 trial confirms that DNA and recombinant adenovirus-based vaccines can elicit robust, cross-clade binding antibodies and target the protective V1V2 region. A key takeaway is the effectiveness of the DNA prime/rAd5 boost (T2) in maximizing the magnitude of V1V2 responses, and the utility of rAd35 in bypassing pre-existing vector immunity.

However, it is important to note that the study focused on binding antibodies (which attach to the virus) rather than neutralizing antibodies (which actively block infection). While V1V2 binding antibodies are a known correlate of protection, they do not guarantee high-level efficacy on their own. Future work will need to focus on optimizing these regimens to improve the durability of the immune response and potentially induce neutralizing capabilities.

Summary updated

Abstract

High frequency responses were elicited against clade A (T1 95.8%, T2 100%, T3 97.4%, T4 100%), clade B (T1 95.8%, T2 95.0%, T3 92.1%, T4 96.3%), clade C (T1 92%, T2 76%, T3 76%, T4 78%), and Con S (T1-4 100%). There were no significant between-group differences in response frequency or magnitude. The majority also had responses to V1V2 clade A (T1 100%, T2 87.8%, T3 83.8%, T4 85.2%) and clade B (T1 58.3%, T2 65.9%, T3 54.1%, T4 51.9%). The mean fluorescent intensity was higher in T2 vs T1 (p=0.005) for clade A V1V2. No significant differences were observed between other groups.
BibTeX
@inproceedings{fuchs2012dna,
  author = {JD Fuchs and Cecilia Morgan and Pierre‐Alexandre Bart and Nidhi Kochar and Nicole Frahm and Edith Swann and Peter B. Gilbert and Stephen C. DeRosa and B Graham and GJ Nabel and Hua‐Xin Liao and Barton F. Haynes and Georgia D. Tomaras},
  title = {{DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies}},
  booktitle = {Retrovirology},
  year = {2012},
  doi = {10.1186/1742-4690-9-s2-p136},
}
Figure